Stability Testing of New Drug Substances and Products
ICH Q1A(R2) defines the stability data package needed to support a marketing application for a new drug substance and product across the ICH regions. It sets the storage conditions, testing frequency, batch selection, container-closure evaluation, and specification framework used to establish a re-test period or shelf life. It requires long-term data at 25°C/60% RH (or 30°C/65% RH), intermediate at 30°C/65% RH, and accelerated at 40°C/75% RH, with a minimum of twelve months long-term and six months accelerated data at submission. It anchors the wider ICH Q1 stability series.
What this does not cover
stated in the document's own scope- It does not cover biotechnological or biological products, whose stability is addressed by ICH Q5C.
- It does not set the acceptance criteria or analytical procedures for the specification itself; those come from ICH Q6A.
- It does not give the detailed statistical evaluation and shelf-life extrapolation method, which are elaborated in ICH Q1E.
- It does not cover bracketing and matrixing study designs in detail, which are the subject of ICH Q1D.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
ICH Q1A(R2) is the foundational stability guideline in the ICH framework. It tells sponsors how much stability data to generate, under which storage conditions, and how to use that data to justify a re-test period for a drug substance or a shelf life for a drug product. The guideline covers batch selection, testing frequency, container-closure, specification, stress and photostability testing, and the evaluation and extrapolation rules that turn raw stability results into an approved storage statement and expiry. It applies to new chemical entities intended for the ICH regions.
Legal basis & how it acquires force
ICH Q1A(R2) is a harmonised guideline, not a statute; it acquires force when each ICH region adopts it into its own framework. In the United States the FDA issues it as guidance implementing the CGMP and marketing-application requirements of 21 CFR 211 and 314; the EMA adopts it as a CHMP scientific guideline under Directive 2001/83/EC; Japan's PMDA issues it as an MHLW notification. Once adopted, a marketing application in that region is expected to present a stability package consistent with the guideline.
Document structure
| Part | Covers |
|---|---|
| Scope and general principles | Application to new drug substances and products for the ICH regions, and the objective of establishing a re-test period or shelf life. |
| Drug substance | Stress testing, batch selection, container-closure, specification, testing frequency, storage conditions, and the stability commitment for the active. |
| Drug product | Photostability, batch selection, container-closure, specification, testing frequency, and storage conditions for the finished dosage form. |
| Storage condition sets | Long-term, intermediate, and accelerated conditions, plus conditions for refrigerated, frozen, and low-temperature products. |
| Data evaluation and extrapolation | Significant-change criteria and the systematic approach to analysing results and proposing a shelf life, elaborated in Q1E. |
Key requirements
- Place at least three primary batches of the drug substance and product on long-term, intermediate, and accelerated stability study.
- Store samples at long-term 25°C/60% RH (or 30°C/65% RH), intermediate 30°C/65% RH, and accelerated 40°C/75% RH conditions.
- Provide a minimum of twelve months long-term and six months accelerated data at the time of submission.
- Test at 0, 3, 6, 9, 12, 18, 24, and 36 months across the long-term study, with more frequent points on the accelerated and intermediate arms.
- Conduct stress testing on the drug substance, including photostability per ICH Q1B, to identify degradation pathways and confirm the method is stability-indicating.
- Evaluate the container-closure system that mirrors the intended market packaging.
- Define a significant change and apply it to trigger intermediate testing and to constrain shelf-life extrapolation per ICH Q1E.
Implementation tips
- Tie your proposed re-test period or shelf life to the actual long-term data trend, and reserve extrapolation for where Q1E genuinely supports it.
- Build the stability-indicating method and its forced-degradation package before the primary batches go on study, so the specification can detect the real degradants.
- Bracket and matrix deliberately per Q1D where strengths, container sizes, or fills justify it, and document the design rationale up front.
- Align the stability specification with the release specification under ICH Q6A so shelf-life limits and release limits stay internally consistent.
International alignment
Q1A(R2) heads the ICH Q1 stability series and is applied with Q1B (photostability), Q1C (new dosage forms), Q1D (bracketing and matrixing), and Q1E (evaluation). It is adopted by FDA, EMA, PMDA, Health Canada, and the many national regulators that reference ICH. A consolidated ICH Q1 merging Q1A-Q1F and Q5C reached Step 2 draft in 2025 but has not reached Step 4, so Q1A(R2) remains in force.
ICH Q1A(R2): frequently asked questions
Quick answers to common questions about ICH Q1A(R2).
What long-term storage condition does ICH Q1A(R2) specify?
Long-term testing is conducted at 25°C ± 2°C / 60% RH ± 5% RH, or alternatively at 30°C ± 2°C / 65% RH ± 5% RH. Accelerated testing is at 40°C ± 2°C / 75% RH ± 5% RH, and the intermediate condition is 30°C ± 2°C / 65% RH ± 5% RH.
How much stability data is needed at the time of submission?
A minimum of twelve months of long-term data and six months of accelerated data on at least three primary batches, with a commitment to continue the studies through the proposed re-test period or shelf life.
How many batches must be placed on stability?
At least three primary batches of the drug substance and of the drug product, generally manufactured at pilot scale or larger and representative of the intended commercial process.
Is ICH Q1A(R2) still current given the 2025 consolidated Q1 draft?
Yes. The consolidated ICH Q1 reached a Step 2 draft in 2025 but has not reached Step 4 adoption, so Q1A(R2) remains the in-force stability guideline.